Silk Road Medical Appoints Andrew Davis as Executive Vice President of Global Sales

Silk Road Medical Appoints Andrew Davis as Executive Vice President of Global Sales

Medical device sales leader to launch new procedure, TCAR, to treat patients at risk for stroke with carotid artery disease.

SUNNYVALE, Calif., May 28, 2015 /PRNewswire/ — Silk Road Medical, Inc., a pioneer in the development of transcarotid therapies for intra and extracranial vascular diseases, announces the appointment of Andrew (Andy) Davis to the position of Executive Vice President of Global Sales. In this new role, Andy will assemble a sales organization and lead the company’s commercialization efforts for the TransCarotid Artery Revascularization (TCAR) procedure with the ENROUTE® Transcarotid Neuroprotection System (NPS) and the ENROUTE® Transcarotid Stent System.
Prior to joining Silk Road Medical, Andy was the Vice President of Sales and Marketing at Acelity’s Advanced Wound Therapy Group and previously held Vice President of Sales positions for Medtronic’s CoreValve, Endovascular, Peripheral and Spinal/Biologics divisions. He has over 20 years of experience in the medical device field with deep expertise in launching innovative, minimally invasive therapies that increase patient access and solve unmet clinical needs in cardiovascular diseases historically treated with invasive surgical approaches.
“Andy is the ideal sales leader to help Silk Road redefine carotid artery revascularization and realize its mission to beat stroke and its devastating effects on patients, families and society,” said Erica Rogers, Chief Executive Officer. “Andy’s deep knowledge of endovascular surgery, extensive relationships, and track record of success will be incredibly valuable to our team as we commercialize in the US and beyond.”
“Silk Road has completely changed the way we think about treating carotid artery disease,” said Davis. “There are known and sometimes severe complications with open carotid surgery, and transfemoral carotid stenting with current technology actually increases the stroke risk. TCAR is a clinically proven game-changer, as demonstrated by the ROADSTER trial, with the clear potential to become standard of care.”
“We have built and trained a world class field organization and achieved significant commercial momentum in a limited market release of our TCAR products,” stated Erica Rogers, President and CEO, Silk Road Medical. “The arrival of the next generation ENROUTE NPS will allow us to commence full commercial launch and continue our quest towards establishing TCAR as the standard of care in preventing strokes from severe carotid artery disease.”

About Silk Road Medical

Silk Road Medical, Inc. is a private company located in Sunnyvale, CA, that develops and manufactures less-invasive medical devices intended to improve the treatment of carotid artery disease through proprietary transcarotid therapies. Detailed information can be found at

About TCAR with the ENROUTE Transcarotid Neuroprotection and Stent System

TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. The ENROUTE Transcarotid Stent is intended to be used in conjunction with the ENROUTE Transcarotid Neuroprotection System (NPS) during the TCAR procedure. The ENROUTE Transcarotid NPS is a first in class device used to directly access the common carotid artery and initiate high rate temporary blood flow reversal to protect the brain from stroke while delivering and implanting the ENROUTE Transcarotid Stent.

Silk Road and ENROUTE are registered trademarks of Silk Road Medical, Inc.
SOURCE Silk Road Medical, Inc.

  • ©2018 Silk Road Medical

  • 1213 Innsbruck Drive
    Sunnyvale, CA 94089

    phone: 855.410.TCAR (8227)
    local phone: 408.720.9002
    fax: 408.720.9013